$0.69
▲ +9.3% Today
as of Aug 5, 16:48 ET
Last 30 days
Recent Press Releases & News
Evogene Schedules Second Quarter 2026 Financial Results Release
Evogene and ELEO to develop new oral PCSK9 inhibitors
Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors
Overview
52-week range
$0.52
$2.42
9% of range
Avg surprise (last 0)
—
Avg reaction (last 2)
-4.5%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 20, 2026 | Mar/2026 | $-0.60 | — | — | -57.9% | -2.7% | earnings |
| Tue Aug 19, 2025 | Jun/2025 | $-0.62 | — | — | — | — | earnings |
| Wed May 21, 2025 | Mar/2025 | $-0.38 | — | — | — | -6.3% | earnings |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 18, 2026 | Jun/2026 | BMO | — | -$0.62 |
Implied volatility — last 90 days
No IV snapshots yet for EVGN.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.